We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 12.50 | 0.76% | 1,653.00 | 1,654.00 | 1,655.00 | 1,655.50 | 1,634.00 | 1,638.50 | 3,961,351 | 16:35:15 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.83 | 68.14B |
From Apr 2019 to Apr 2024
TIDMGSK
RNS Number : 2287X
GlaxoSmithKline PLC
17 February 2017
GlaxoSmithKline plc (the 'Company')
Conditional Share Awards
This notification sets out the vesting details of Deferred Bonus Awards over Ordinary Shares and American Depositary Shares made in 2014 under the GlaxoSmithKline 2009 Deferred Annual Bonus Plan (DABP) and the associated Matching Awards, which were subject to relevant business performance conditions. The three-year performance period for the 2014 awards commenced on 1 January 2014 and ended on 31 December 2016 and the restricted period has come to an end.
The performance measure vesting details are as follows:
Hot Features
Premium
Portion Measure Outcome Overall
of the outcome
Award
--------- -------------------------------------------- ---------- ---------
Adjusted free cash flow - The Company
did not meet the threshold level of
performance for adjusted free cash Lapsed
1/3(rd) flow for the three year period. in full 0%
--------- -------------------------------------------- ---------- ---------
TSR measure - For the three years
ending 31 December 2016, the Company's
TSR ranked 9(th) (i.e. below median)
against a comparator group of 10 global
pharmaceutical companies including Lapsed
1/3(rd) GSK. in full 0%
--------- -------------------------------------------- ---------- ---------
R&D New Products sales measure - For
the three year period, the Company
achieved New Product sales calculated
in accordance with the principles
for the measure of GBP6.717bn, which
was above the maximum vesting level
of GBP4.428bn (the threshold level
was GBP3.623bn) after appropriate
adjustments for the implications of Vested
1/3(rd) the three-part transaction with Novartis. in full 33.33%
--------- -------------------------------------------- ---------- ---------
Total vesting for 2014 award 33.33%
Lapsed 66.67%
-------------------------------------------------------- ---------
The notifications that follow are for awards made to Persons Discharging Managerial Responsibilities (PDMRs) and show the vesting of the Deferred Bonus Awards including dividends accrued and the proportion of the Matching Awards i.e., conditional awards that vested including dividends accrued on the awards which vested in the same proportion, subject to performance, as the underlying shares on 16 February 2017. The balance of these awards made to each PDMR has lapsed.
The closing prices of an Ordinary Share and of an ADS of GlaxoSmithKline plc at the point of vesting on 16 February 2017 were GBP16.17 and $40.92 respectively.
Transaction notification
1. Details of PDMR/person closely associated with them
('PCA')
=== ========================================================================
a) Name Sir Andrew Witty
=== ======================== ==============================================
b) Position/status Chief Executive Officer
=== ======================== ==============================================
c) Initial notification/ Initial notification
amendment
=== ======================== ==============================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ==============================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ==============================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ========================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ==============================================
b) Nature of the The number of Ordinary Shares released
transaction on awards granted in 2014 under the Company's
2009 Deferred Annual Bonus Plan-Deferred
Bonus and Matching Awards.
=== ======================== ==============================================
c) Price(s) and Price(s) Volume(s)
volume(s) --------- ------------------
GBP0.00 67,867 (Deferred)
--------- ------------------
GBP0.00 22,621 (Matching)
--------- ------------------
=== ======================== ==============================================
d) Aggregated information
Aggregated volume 90,488
Price GBP0.00
=== ======================== ==============================================
e) Date of the transaction 2017-02-16
=== ======================== ==============================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ======================== ==============================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ========================================================================
a) Name Ms Emma Walmsley
=== ======================== ==============================================
b) Position/status CEO Designate
=== ======================== ==============================================
c) Initial notification/ Initial notification
amendment
=== ======================== ==============================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ==============================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ==============================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ========================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ==============================================
b) Nature of the The number of Ordinary Shares released
transaction on awards granted in 2014 under the Company's
2009 Deferred Annual Bonus Plan-Deferred
Bonus and Matching Awards.
=== ======================== ==============================================
c) Price(s) and Price(s) Volume(s)
volume(s) --------- ------------------
GBP0.00 14,860 (Deferred)
--------- ------------------
GBP0.00 4,954 (Matching)
--------- ------------------
=== ======================== ==============================================
d) Aggregated information
Aggregated volume 19,814
Price GBP0.00
=== ======================== ==============================================
e) Date of the transaction 2017-02-16
=== ======================== ==============================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ======================== ==============================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ========================================================================
a) Name Mr R G Connor
=== ======================== ==============================================
b) Position/status President, Global Manufacturing & Supply
=== ======================== ==============================================
c) Initial notification/ Initial notification
amendment
=== ======================== ==============================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ==============================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ==============================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ========================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ==============================================
b) Nature of the The number of Ordinary Shares released
transaction on awards granted in 2014 under the Company's
2009 Deferred Annual Bonus Plan-Deferred
Bonus and Matching Awards.
=== ======================== ==============================================
c) Price(s) and Price(s) Volume(s)
volume(s) --------- ------------------
GBP0.00 13,284 (Deferred)
--------- ------------------
GBP0.00 4,428 (Matching)
--------- ------------------
=== ======================== ==============================================
d) Aggregated information
Aggregated volume 17,712
Price GBP0.00
=== ======================== ==============================================
e) Date of the transaction 2017-02-16
=== ======================== ==============================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ======================== ==============================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ========================================================================
a) Name Mr S Dingemans
=== ======================== ==============================================
b) Position/status Chief Financial Officer
=== ======================== ==============================================
c) Initial notification/ Initial notification
amendment
=== ======================== ==============================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ==============================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ==============================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ========================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ==============================================
b) Nature of the The number of Ordinary Shares released
transaction on awards granted in 2014 under the Company's
2009 Deferred Annual Bonus Plan-Deferred
Bonus and Matching Awards.
=== ======================== ==============================================
c) Price(s) and Price(s) Volume(s)
volume(s) --------- ------------------
GBP0.00 22,448 (Deferred)
--------- ------------------
GBP0.00 7,483 (Matching)
--------- ------------------
=== ======================== ==============================================
d) Aggregated information
Aggregated volume 29,931
Price GBP0.00
=== ======================== ==============================================
e) Date of the transaction 2017-02-16
=== ======================== ==============================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ======================== ==============================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ========================================================================
a) Name Mr S A Hussain
=== ======================== ==============================================
b) Position/status President, Global Pharmaceuticals
=== ======================== ==============================================
c) Initial notification/ Initial notification
amendment
=== ======================== ==============================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ==============================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ==============================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ========================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ==============================================
b) Nature of the The number of Ordinary Shares released
transaction on awards granted in 2014 under the Company's
2009 Deferred Annual Bonus Plan-Deferred
Bonus and Matching Awards.
=== ======================== ==============================================
c) Price(s) and Price(s) Volume(s)
volume(s) --------- -----------------
GBP0.00 9,743 (Deferred)
--------- -----------------
GBP0.00 3,248 (Matching)
--------- -----------------
=== ======================== ==============================================
d) Aggregated information
Aggregated volume 12,991
Price GBP0.00
=== ======================== ==============================================
e) Date of the transaction 2017-02-16
=== ======================== ==============================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ======================== ==============================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ========================================================================
a) Name Mr D S Redfern
=== ======================== ==============================================
b) Position/status Chief Strategy Officer
=== ======================== ==============================================
c) Initial notification/ Initial notification
amendment
=== ======================== ==============================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ==============================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ==============================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ========================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ==============================================
b) Nature of the The number of Ordinary Shares released
transaction on awards granted in 2014 under the Company's
2009 Deferred Annual Bonus Plan-Deferred
Bonus and Matching Awards.
=== ======================== ==============================================
c) Price(s) and Price(s) Volume(s)
volume(s) --------- ------------------
GBP0.00 12,115 (Deferred)
--------- ------------------
GBP0.00 4,039 (Matching)
--------- ------------------
=== ======================== ==============================================
d) Aggregated information
Aggregated volume 16,154
Price GBP0.00
=== ======================== ==============================================
e) Date of the transaction 2017-02-16
=== ======================== ==============================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ======================== ==============================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ===========================================================================
a) Name Dr M M Slaoui
==== ========================= ================================================
b) Position/status Chairman, Global Vaccines
==== ========================= ================================================
c) Initial notification/ Initial notification
amendment
==== ========================= ================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ===========================================================================
a) Name GlaxoSmithKline plc
==== ========================= ================================================
b) LEI 5493000HZTVUYLO1D793
==== ========================= ================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ===========================================================================
a) Description of GlaxoSmithKline plc American Depositary
the financial Shares ('ADSs')
instrument ISIN: US37733W1053
==== ========================= ================================================
b) Nature of the The number of ADSs released on awards granted
transaction in 2014 under the Company's 2009 Deferred
Annual Bonus Plan--Deferred Bonus and Matching
Awards.
==== ========================= ================================================
c) Price(s) and Price(s) Volume(s)
volume(s) --------- ------------------
$0.00 21,645 (Deferred)
--------- ------------------
$0.00 7,215 (Matching)
--------- ------------------
==== ========================= ================================================
d) Aggregated information
Aggregated volume 28,860
Price $0.00
============================== ================================================
e) Date of the transaction 2017-02-16
==== ========================= ================================================
f) Place of the n/a
transaction
==== ========================= ================================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ========================================================================
a) Name Ms C Thomas
=== ======================== ==============================================
b) Position/status SVP, Human Resources
=== ======================== ==============================================
c) Initial notification/ Initial notification
amendment
=== ======================== ==============================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ==============================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ==============================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ========================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ==============================================
b) Nature of the The number of Ordinary Shares released
transaction on awards granted in 2014 under the Company's
2009 Deferred Annual Bonus Plan-Deferred
Bonus and Matching Awards.
=== ======================== ==============================================
c) Price(s) and Price(s) Volume(s)
volume(s) --------- -----------------
GBP0.00 7,517 (Deferred)
--------- -----------------
GBP0.00 2,506 (Matching)
--------- -----------------
=== ======================== ==============================================
d) Aggregated information
Aggregated volume 10,023
Price GBP0.00
=== ======================== ==============================================
e) Date of the transaction 2017-02-16
=== ======================== ==============================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ======================== ==============================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ========================================================================
a) Name Mr P C Thomson
=== ======================== ==============================================
b) Position/status SVP, Communications & Government Affairs
=== ======================== ==============================================
c) Initial notification/ Initial notification
amendment
=== ======================== ==============================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ==============================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ==============================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ========================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ==============================================
b) Nature of the The number of Ordinary Shares released
transaction on awards granted in 2014 under the Company's
2009 Deferred Annual Bonus Plan-Deferred
Bonus and Matching Awards.
=== ======================== ==============================================
c) Price(s) and Price(s) Volume(s)
volume(s) --------- -----------------
GBP0.00 4,528 (Deferred)
--------- -----------------
GBP0.00 1,509 (Matching)
--------- -----------------
=== ======================== ==============================================
d) Aggregated information
Aggregated volume
Price 6,037
GBP0.00
=== ======================== ==============================================
e) Date of the transaction 2017-02-16
=== ======================== ==============================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ======================== ==============================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ===========================================================================
a) Name Mr D E Troy
==== ========================= ================================================
b) Position/status SVP & General Counsel
==== ========================= ================================================
c) Initial notification/ Initial notification
amendment
==== ========================= ================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ===========================================================================
a) Name GlaxoSmithKline plc
==== ========================= ================================================
b) LEI 5493000HZTVUYLO1D793
==== ========================= ================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ===========================================================================
a) Description of GlaxoSmithKline plc American Depositary
the financial Shares ('ADSs')
instrument ISIN: US37733W1053
==== ========================= ================================================
b) Nature of the The number of ADSs released on awards granted
transaction in 2014 under the Company's 2009 Deferred
Annual Bonus Plan--Deferred Bonus and Matching
Awards.
==== ========================= ================================================
c) Price(s) and Price(s) Volume(s)
volume(s) --------- -----------------
$0.00 8,762 (Deferred)
--------- -----------------
$0.00 2,920 (Matching)
--------- -----------------
==== ========================= ================================================
Aggregated information
Aggregated volume
d) Price 11,682 $0.00
==== ========================= ================================================
e) Date of the transaction 2017-02-16
==== ========================= ================================================
f) Place of the n/a
transaction
==== ========================= ================================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ========================================================================
a) Name Dr P J T Vallance
=== ======================== ==============================================
b) Position/status President, R&D
=== ======================== ==============================================
c) Initial notification/ Initial notification
amendment
=== ======================== ==============================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ==============================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ==============================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ========================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ==============================================
b) Nature of the The number of Ordinary Shares released
transaction on awards granted in 2014 under the Company's
2009 Deferred Annual Bonus Plan-Deferred
Bonus and Matching Awards.
=== ======================== ==============================================
c) Price(s) and Price(s) Volume(s)
volume(s) --------- ------------------
GBP0.00 26,863 (Deferred)
--------- ------------------
GBP0.00 8,954 (Matching)
--------- ------------------
=== ======================== ==============================================
d) Aggregated information
Aggregated volume
Price 35,817
GBP0.00
=== ======================== ==============================================
e) Date of the transaction 2017-02-16
=== ======================== ==============================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ======================== ==============================================
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHEDLFFDLFEBBX
(END) Dow Jones Newswires
February 17, 2017 10:57 ET (15:57 GMT)
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
